General Information of Drug (ID: DM75CXN)

Drug Name
Avanafil
Synonyms Stendra (TN)
Indication
Disease Entry ICD 11 Status REF
Erectile dysfunction HA01.1 Approved [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 483.9
Logarithm of the Partition Coefficient (xlogp) 2.6
Rotatable Bond Count (rotbonds) 9
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 9
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 30-45 min [2]
Elimination
Approximately 62% of a given dose is excreted as metabolites in the feces and approximately 21% as metabolites in the urine [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 5 - 17 hours [3]
Metabolism
The drug is metabolized via the CYP3A4 and to a lesser extent by CYP2C9 [2]
Vd
The volume of distribution (Vd) of drug is 47-83 L [3]
Chemical Identifiers
Formula
C23H26ClN7O3
IUPAC Name
4-[(3-chloro-4-methoxyphenyl)methylamino]-2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-N-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide
Canonical SMILES
COC1=C(C=C(C=C1)CNC2=NC(=NC=C2C(=O)NCC3=NC=CC=N3)N4CCC[C@H]4CO)Cl
InChI
InChI=1S/C23H26ClN7O3/c1-34-19-6-5-15(10-18(19)24)11-27-21-17(22(33)28-13-20-25-7-3-8-26-20)12-29-23(30-21)31-9-2-4-16(31)14-32/h3,5-8,10,12,16,32H,2,4,9,11,13-14H2,1H3,(H,28,33)(H,27,29,30)/t16-/m0/s1
InChIKey
WEAJZXNPAWBCOA-INIZCTEOSA-N
Cross-matching ID
PubChem CID
9869929
ChEBI ID
CHEBI:66876
CAS Number
330784-47-9
DrugBank ID
DB06237
TTD ID
D0Y5JC
INTEDE ID
DR0159
ACDINA ID
D00052
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Phosphodiesterase 5A (PDE5A) TTJ0IQB PDE5A_HUMAN Modulator [4]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME
DE4LYSA CP3A4_HUMAN Substrate [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Erectile dysfunction
ICD Disease Classification HA01.1
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Phosphodiesterase 5A (PDE5A) DTT PDE5A 1.60E-01 -0.25 -0.99
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 3.90E-02 -3.45E-01 -1.49E+00
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Avanafil (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Moderate Increased metabolism of Avanafil caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [6]
Arn-509 DMT81LZ Moderate Increased metabolism of Avanafil caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [6]
Troleandomycin DMUZNIG Major Decreased metabolism of Avanafil caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [7]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Avanafil caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [6]
Tucatinib DMBESUA Major Decreased metabolism of Avanafil caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [7]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Avanafil caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [8]
MK-8228 DMOB58Q Major Decreased metabolism of Avanafil caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [6]
Stiripentol DMMSDOY Major Decreased metabolism of Avanafil caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [6]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Avanafil caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [6]
Tazemetostat DMWP1BH Moderate Increased metabolism of Avanafil caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [6]
Boceprevir DMBSHMF Major Decreased metabolism of Avanafil caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [7]
Simeprevir DMLUA9D Moderate Decreased metabolism of Avanafil caused by Simeprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [9]
Cobicistat DM6L4H2 Major Decreased metabolism of Avanafil caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [7]
Etravirine DMGV8QU Moderate Increased metabolism of Avanafil caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [6]
Lesinurad DMUR64T Moderate Increased metabolism of Avanafil caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [6]
Berotralstat DMWA2DZ Major Decreased metabolism of Avanafil caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [6]
Crizotinib DM4F29C Major Decreased metabolism of Avanafil caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [6]
Ceritinib DMB920Z Major Decreased metabolism of Avanafil caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [7]
PF-06463922 DMKM7EW Moderate Increased metabolism of Avanafil caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [6]
Selpercatinib DMZR15V Moderate Decreased metabolism of Avanafil caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [10]
Idelalisib DM602WT Major Decreased metabolism of Avanafil caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [7]
IPI-145 DMWA24P Major Decreased metabolism of Avanafil caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [6]
Vemurafenib DM62UG5 Moderate Increased metabolism of Avanafil caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [6]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Avanafil caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [6]
Ozanimod DMT6AM2 Moderate Additive hypotensive effects by the combination of Avanafil and Ozanimod. Multiple sclerosis [8A40] [11]
Fedratinib DM4ZBK6 Major Decreased metabolism of Avanafil caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [6]
Netupitant DMEKAYI Major Decreased metabolism of Avanafil caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [12]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Avanafil caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [13]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Avanafil and Safinamide. Parkinsonism [8A00] [11]
Abametapir DM2RX0I Moderate Decreased metabolism of Avanafil caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [14]
Lefamulin DME6G97 Moderate Decreased metabolism of Avanafil caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [15]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Avanafil caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [7]
Enzalutamide DMGL19D Moderate Increased metabolism of Avanafil caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [6]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Avanafil caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [16]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Avanafil caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [10]
Larotrectinib DM26CQR Moderate Decreased metabolism of Avanafil caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [7]
Armodafinil DMGB035 Minor Increased metabolism of Avanafil caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [17]
LEE011 DMMX75K Major Decreased metabolism of Avanafil caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [6]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Avanafil caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [18]
Elagolix DMB2C0E Moderate Increased metabolism of Avanafil caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [6]
⏷ Show the Full List of 40 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Calcium carbonate E00198 10112 Binding agent; Buffering agent; Diluent; Opacifying agent
Fumaric acid E00420 444972 Acidulant; Antioxidant; Complexing agent; Flavoring agent; Solubilizing agent
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Magnesium stearate E00208 11177 lubricant
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Avanafil 100 mg tablet 100 mg Oral Tablet Oral
Avanafil 200 mg tablet 200 mg Oral Tablet Oral
Avanafil 50 mg tablet 50 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7448).
2 FDA Approved Drug Products: Stendra (avanafil) tablets for oral use
3 EMA CHMP Assessment Report: Avanafil (INN)
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors. Expert Opin Pharmacother. 2013 Jul;14(10):1333-44.
6 Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
7 Cerner Multum, Inc. "Australian Product Information.".
8 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
9 Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
10 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
11 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
12 Product Information. Cialis (tadalafil). Lilly, Eli and Company, Indianapolis, IN.
13 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
14 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
15 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
16 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
17 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
18 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.